Becker Muscular Dystrophy (BMD)

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

Becker Muscular Dystrophy (BMD) is a genetic disorder that primarily affects the muscles, causing them to become weak and less functional over time. It is a condition that mainly involves the skeletal muscles, which are responsible for movement, and can also affect the heart muscle. People with BMD often experience difficulty walking, muscle cramps, and fatigue. The disease usually starts in childhood or adolescence but progresses more slowly than similar conditions. It is caused by changes in a gene that affects a protein important for muscle strength and stability. Over time, muscle weakness can impact daily activities and overall health.

Clinical Definition

Becker Muscular Dystrophy (BMD) is an X-linked recessive muscle disorder characterized by mutations in the DMD gene leading to reduced or abnormal dystrophin protein production. This protein is essential for maintaining the structural integrity of muscle fibers during contraction. Unlike Duchenne muscular dystrophy, BMD typically presents with a later onset and slower progression due to partially functional dystrophin. The disease primarily affects proximal muscles of the pelvic and shoulder girdles, causing progressive muscle weakness and wasting. Cardiac involvement, including dilated cardiomyopathy, is a major cause of morbidity. Diagnosis is important for genetic counseling and management of complications.

Inciting Event

  • A pathogenic DMD gene variant causes disease; it can be inherited or arise de novo, so absent family history does not exclude BMD.

  • Progressive muscle damage begins insidiously as dystrophin deficiency impairs muscle fiber stability.

Latency Period

  • Symptoms typically develop gradually over years to decades after birth.

  • Muscle weakness often becomes apparent in late childhood or adolescence.

  • Diagnosis is often delayed due to slow progression and mild early symptoms.

Diagnostic Delay

  • Mild or slowly progressive symptoms lead to misattribution to benign muscle fatigue or growth-related weakness.

  • Lack of awareness of Becker muscular dystrophy in late-onset muscle weakness delays diagnosis.

  • Normal early developmental milestones and absence of severe symptoms reduce clinical suspicion.

  • Misdiagnosis as other neuromuscular disorders or orthopedic conditions is common.

Clinical Presentation


Signs & Symptoms

  • Progressive proximal muscle weakness usually presenting in adolescence or early adulthood

  • Exercise intolerance and muscle cramps

  • Fatigue during physical activity

  • Delayed motor milestones may be present but less severe than Duchenne muscular dystrophy

  • Cardiomyopathy may be clinically silent or disproportionate to skeletal weakness; palpitations, dyspnea or syncope warrant assessment, but surveillance should precede symptoms.

History of Present Illness

  • Gradual onset of proximal muscle weakness, especially in the pelvic and shoulder girdle muscles.

  • Difficulty with activities such as running, climbing stairs, and rising from the floor.

  • Exercise-related cramps and myalgia can be prominent early findings, sometimes preceding recognizable weakness.

  • Calf enlargement is often pseudohypertrophy from fatty/connective-tissue replacement; enlargement does not imply normal muscle strength.

  • Symptoms progress slowly, with many patients remaining ambulatory into adulthood.

Past Medical History

  • Elevated serum creatine kinase levels may have been noted incidentally or during evaluation for muscle symptoms.

  • Review exercise-related myalgia, dark urine/rhabdomyolysis, drug exposures and prior neuromuscular evaluations; an acute muscle-injury episode does not exclude underlying dystrophinopathy.

  • Absence of cardiac symptoms does not exclude myocardial disease. Review prior cardiac imaging, rhythm assessment and respiratory function.

Family History

  • X-linked inheritance pattern with affected male relatives such as maternal uncles or cousins.

  • Female relatives may have normal or elevated CK, skeletal symptoms or isolated cardiomyopathy; normal CK does not rule out a familial DMD variant.

  • Family history of muscular dystrophy or unexplained muscle weakness supports diagnosis.

Physical Exam Findings

  • Calf pseudohypertrophy due to fatty infiltration and fibrosis of muscle tissue

  • Proximal muscle weakness, especially in the pelvic and shoulder girdle muscles

  • Gower sign positive indicating proximal lower limb weakness

  • Decreased deep tendon reflexes in affected muscles

  • Mild to moderate muscle atrophy in later stages

Diagnostic Workup


Diagnostic Criteria

Suspect BMD from a compatible pattern of weakness/cramps, elevated CK and family history, while recognizing de novo disease. DMD gene deletion/duplication analysis and sequencing establish a molecular dystrophinopathy diagnosis; clinical course helps classify Becker versus Duchenne. In-frame variants often allow partially functional dystrophin, but the reading-frame rule has exceptions. Muscle biopsy/protein analysis is reserved mainly for unresolved cases, rather than routinely required after a clear genetic diagnosis. Evaluate cardiac function at diagnosis.

Pathophysiology


Key Mechanisms

  • Abnormal/reduced dystrophin weakens the connection between the intracellular actin cytoskeleton and the extracellular matrix through the dystrophin-associated complex, making muscle fibers vulnerable to contraction-related injury.

  • Partial preservation of dystrophin allows for a milder phenotype compared to Duchenne muscular dystrophy.

  • Loss of sarcolemmal integrity results in increased calcium influx and activation of proteases causing muscle cell damage.

  • Chronic muscle damage triggers fibrosis and fatty replacement of muscle tissue, impairing function.

  • Repeated degeneration and incomplete regeneration lead to progressive loss of functional fibers; this is more complex than a universal, proven exhaustion of satellite cells in every patient.

InvolvementDetails
Organs

Skeletal muscles are primarily involved causing progressive proximal muscle weakness and calf hypertrophy.

Heart is commonly affected with dilated cardiomyopathy and arrhythmias in Becker muscular dystrophy.

Tissues

Skeletal muscle tissue undergoes progressive fibrosis and fatty replacement leading to weakness and wasting.

Cardiac muscle tissue is affected by fibrosis and dilated cardiomyopathy contributing to morbidity.

Cells

Skeletal muscle fibers are the primary affected cells undergoing progressive degeneration due to defective dystrophin protein.

Cardiomyocytes are involved in the development of dilated cardiomyopathy seen in Becker muscular dystrophy.

Chemical Mediators

Creatine kinase is elevated in serum as a marker of ongoing muscle damage in Becker muscular dystrophy.

Dystrophin deficiency due to mutations in the DMD gene leads to muscle fiber fragility and degeneration.

Treatments


Pharmacological Treatments

  • Corticosteroids (e.g., prednisone, deflazacort)

    • Mechanism:
      • Glucocorticoids alter gene transcription and inflammatory signaling; possible functional benefit in selected BMD does not restore the underlying dystrophin gene.

    • Side effects:
      • Weight gain

      • Osteoporosis

      • Hypertension

      • Glucose intolerance

    • Clinical role:
      • Not a universally established first-line BMD treatment. A neuromuscular specialist may consider a monitored trial in selected significant/progressive weakness; evidence is much less robust than for Duchenne.

  • ACE inhibitors

    • Mechanism:
      • Prevent or delay cardiomyopathy progression by reducing cardiac afterload and fibrosis.

    • Side effects:
      • Hypotension

      • Hyperkalemia

      • Cough

    • Clinical role:
      • Cardioprotective treatment when early myocardial disease or ventricular dysfunction is identified, tailored by cardiology; do not wait for symptomatic heart failure.

  • Beta blockers

    • Mechanism:
      • Reduce cardiac workload and arrhythmia risk in cardiomyopathy associated with BMD.

    • Side effects:
      • Bradycardia

      • Fatigue

      • Bronchospasm

    • Clinical role:
      • Used for appropriate ventricular dysfunction, heart failure or arrhythmia indications under cardiology guidance, rather than automatically for every asymptomatic patient.

Non-pharmacological Treatments

  • Physical/occupational therapy emphasizes range of motion, contracture prevention and safe submaximal activity, individualized to cardiac and muscle status.

  • Use of assistive devices such as braces or wheelchairs to improve mobility and prevent falls.

  • Perform cardiac assessment at diagnosis and serial surveillance, even without symptoms; ECG and echocardiography, with cardiac MRI when appropriate, assess rhythm, ventricular function and fibrosis.

  • Respiratory support including non-invasive ventilation in cases of respiratory muscle weakness.

Prevention


Pharmacological Prevention

  • Corticosteroids do not prevent BMD. Selected use for muscle function requires individualized discussion of uncertain benefit and risks including bone loss, weight gain and adrenal suppression.

  • Cardiac surveillance guides early ACE inhibitor/other heart-failure therapy when indicated; treatment can start before cardiac symptoms.

  • Routine anticoagulation solely for chronic reduced mobility is not standard prevention. Use established indications or an individualized acute hospital/surgical VTE risk assessment.

Non-pharmacological Prevention

  • Regular physical therapy to maintain muscle strength and prevent contractures

  • Cardiac monitoring with echocardiography and ECG for early detection of cardiomyopathy

  • Respiratory function testing to monitor for decline and initiate support

  • Orthotic devices to improve mobility and prevent deformities

  • Genetic counseling for affected families

Outcome & Complications


Complications

  • Heart failure due to progressive cardiomyopathy

  • Respiratory failure from weakened respiratory muscles

  • Severe contractures limiting mobility

  • Increased risk of falls and fractures due to muscle weakness

Short-term Sequelae Long-term Sequelae
  • Exercise-induced muscle pain and fatigue

  • Transient muscle cramps

  • Mild functional decline during periods of illness or inactivity

  • Progressive loss of ambulation often occurring in adulthood

  • Chronic cardiomyopathy leading to heart failure

  • Permanent joint contractures and scoliosis

  • Chronic respiratory insufficiency requiring ventilatory support

Differential Diagnoses


Becker Muscular Dystrophy (BMD) versus Duchenne Muscular Dystrophy (DMD)

Becker Muscular Dystrophy (BMD)

Duchenne Muscular Dystrophy (DMD)

Usually later onset than Duchenne, but onset ranges from childhood to later adulthood.

Early childhood onset (before 5 years)

Variable slower progression; many remain ambulatory well into adulthood.

Usually more rapid progression; loss of ambulation historically occurred in the early teens, but treatment can delay it.

DMD gene variant with a compatible milder phenotype; when protein testing is needed, dystrophin is usually reduced/abnormal but partly functional.

DMD gene variant with a compatible severe phenotype; muscle studies usually show absent or very low dystrophin. Genetic testing itself does not measure protein expression.

Becker Muscular Dystrophy (BMD) versus Limb-Girdle Muscular Dystrophy (LGMD)

Becker Muscular Dystrophy (BMD)

Limb-Girdle Muscular Dystrophy (LGMD)

X-linked recessive inheritance

Autosomal recessive inheritance most common

Proximal weakness with frequent calf pseudohypertrophy.

Proximal limb-girdle weakness; calf hypertrophy can occur, including in sarcoglycanopathies.

Mutations in the DMD gene affecting dystrophin

Mutations in various sarcoglycan or other muscle proteins

Becker Muscular Dystrophy (BMD) versus Myotonic Dystrophy

Becker Muscular Dystrophy (BMD)

Myotonic Dystrophy

Clinical myotonia is not a characteristic feature.

Myotonia supports myotonic dystrophy, but can be subtle, especially in type 2.

Skeletal and cardiac muscle disease, with possible respiratory and neurobehavioral involvement; BMD is not confined to limb muscles.

Multisystem features including cataracts, cardiac conduction defects, and endocrine abnormalities

Mutations or deletions in DMD gene

DM1: DMPK CTG repeat expansion. DM2: CNBP CCTG repeat expansion.

Becker Muscular Dystrophy (BMD) versus Inflammatory Myopathies (e.g., Polymyositis)

Becker Muscular Dystrophy (BMD)

Inflammatory Myopathies (e.g., Polymyositis)

Usually slowly progressive weakness; cramps and myalgia can occur.

Often subacute weakness, with variable pain; tempo and pain alone are not definitive.

High CK with a dystrophinopathy phenotype/genotype; CK elevation alone is nonspecific.

CK and relevant antibodies may support myositis, but negative antibodies do not exclude it; interpret clinical findings, imaging/EMG and biopsy as appropriate.

Steroid benefit in BMD is uncertain and individualized; response is not a reliable diagnostic discriminator.

Many autoimmune myopathies respond to immunotherapy, but response varies by subtype and does not alone establish diagnosis.

Becker Muscular Dystrophy (BMD) versus Facioscapulohumeral Muscular Dystrophy (FSHD)

Becker Muscular Dystrophy (BMD)

Facioscapulohumeral Muscular Dystrophy (FSHD)

Proximal limb and calf muscle weakness predominates

Facial and scapular muscle weakness predominates

Adolescence to early adulthood with limb-girdle weakness

Typically adolescence or early adulthood with facial weakness

Mutations or deletions in DMD gene

FSHD1: D4Z4 repeat contraction on a permissive 4q haplotype. FSHD2 involves D4Z4 hypomethylation with a permissive haplotype, often from SMCHD1-related disease.